Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1995 Sep;59(3):280–283. doi: 10.1136/jnnp.59.3.280

Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type.

R E Tato 1, A Frank 1, A Hernanz 1
PMCID: PMC486030  PMID: 7545739

Abstract

Tau protein concentrations were measured in the CSF of 23 patients with dementia of the Alzheimer type (DAT), 36 patients with multi-infarct dementia (MID), and 23 control subjects. Tau protein concentrations were significantly higher in patients with DAT than in controls (P < 0.001) and patients with MID (P < 0.001). A significantly positive correlation between CSF tau protein and glucose concentrations (r = 0.79, P < 0.001) and evolution of disease (r = 0.47, P < 0.05), and a negative correlation with Folstein's mental state examination test (r = -0.73, P < 0.001) were found in patients with DAT.

Full text

PDF
280

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adolfsson R., Bucht G., Lithner F., Winblad B. Hypoglycemia in Alzheimer's disease. Acta Med Scand. 1980;208(5):387–388. doi: 10.1111/j.0954-6820.1980.tb01217.x. [DOI] [PubMed] [Google Scholar]
  2. Arriagada P. V., Growdon J. H., Hedley-Whyte E. T., Hyman B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992 Mar;42(3 Pt 1):631–639. doi: 10.1212/wnl.42.3.631. [DOI] [PubMed] [Google Scholar]
  3. Bancher C., Braak H., Fischer P., Jellinger K. A. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett. 1993 Nov 12;162(1-2):179–182. doi: 10.1016/0304-3940(93)90590-h. [DOI] [PubMed] [Google Scholar]
  4. Beal M. F., Mazurek M. F., Black P. M., Martin J. B. Human cerebrospinal fluid somatostatin in neurologic disease. J Neurol Sci. 1985 Nov;71(1):91–104. doi: 10.1016/0022-510x(85)90039-5. [DOI] [PubMed] [Google Scholar]
  5. Beal M. F., Mazurek M. F., Chattha G. K., Svendsen C. N., Bird E. D., Martin J. B. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Ann Neurol. 1986 Sep;20(3):282–288. doi: 10.1002/ana.410200303. [DOI] [PubMed] [Google Scholar]
  6. Davies P., Katzman R., Terry R. D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature. 1980 Nov 20;288(5788):279–280. doi: 10.1038/288279a0. [DOI] [PubMed] [Google Scholar]
  7. Degrell I., Hellsing K., Nagy E., Niklasson F. Amino acid concentrations in cerebrospinal fluid in presenile and senile dementia of Alzheimer type and multi-infarct dementia. Arch Gerontol Geriatr. 1989 Sep-Oct;9(2):123–135. doi: 10.1016/0167-4943(89)90033-2. [DOI] [PubMed] [Google Scholar]
  8. Ghanbari H. A., Kozuk T., Miller B. E., Riesing S. A sandwich enzyme immunoassay for detecting and measuring Alzheimer's disease--associated proteins in human brain tissue. J Clin Lab Anal. 1990;4(3):189–192. doi: 10.1002/jcla.1860040308. [DOI] [PubMed] [Google Scholar]
  9. Ghanbari H. A., Miller B. E., Haigler H. J., Arato M., Bissette G., Davies P., Nemeroff C. B., Perry E. K., Perry R., Ravid R. Biochemical assay of Alzheimer's disease--associated protein(s) in human brain tissue. A clinical study. JAMA. 1990 Jun 6;263(21):2907–2910. [PubMed] [Google Scholar]
  10. Hoyer S., Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm. 1989;75(3):227–232. doi: 10.1007/BF01258634. [DOI] [PubMed] [Google Scholar]
  11. Khachaturian Z. S. Diagnosis of Alzheimer's disease. Arch Neurol. 1985 Nov;42(11):1097–1105. doi: 10.1001/archneur.1985.04060100083029. [DOI] [PubMed] [Google Scholar]
  12. Khatoon S., Grundke-Iqbal I., Iqbal K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem. 1992 Aug;59(2):750–753. doi: 10.1111/j.1471-4159.1992.tb09432.x. [DOI] [PubMed] [Google Scholar]
  13. Martinez M., Frank A., Hernanz A. Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neuroimmunol. 1993 Nov-Dec;48(2):235–240. doi: 10.1016/0165-5728(93)90197-7. [DOI] [PubMed] [Google Scholar]
  14. Matus A. Microtubule-associated proteins: their potential role in determining neuronal morphology. Annu Rev Neurosci. 1988;11:29–44. doi: 10.1146/annurev.ne.11.030188.000333. [DOI] [PubMed] [Google Scholar]
  15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  16. Mercken M., Vandermeeren M., Lübke U., Six J., Boons J., Vanmechelen E., Van de Voorde A., Gheuens J. Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. J Neurochem. 1992 Feb;58(2):548–553. doi: 10.1111/j.1471-4159.1992.tb09754.x. [DOI] [PubMed] [Google Scholar]
  17. Miller D. C. Is it time to reassess the pathological criteria for a diagnosis of Alzheimer disease? Alzheimer Dis Assoc Disord. 1993 Fall;7(3):129–131. doi: 10.1097/00002093-199307030-00001. [DOI] [PubMed] [Google Scholar]
  18. Morris J. C., McKeel D. W., Jr, Storandt M., Rubin E. H., Price J. L., Grant E. A., Ball M. J., Berg L. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991 Apr;41(4):469–478. doi: 10.1212/wnl.41.4.469. [DOI] [PubMed] [Google Scholar]
  19. Morrison J. H., Rogers J., Scherr S., Benoit R., Bloom F. E. Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients. Nature. 1985 Mar 7;314(6006):90–92. doi: 10.1038/314090a0. [DOI] [PubMed] [Google Scholar]
  20. Mukaetova-Ladinska E. B., Harrington C. R., Roth M., Wischik C. M. Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. Am J Pathol. 1993 Aug;143(2):565–578. [PMC free article] [PubMed] [Google Scholar]
  21. Sakurada T., Alufuzoff I., Winblad B., Nordberg A. Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. Brain Res. 1990 Jun 25;521(1-2):329–332. doi: 10.1016/0006-8993(90)91561-t. [DOI] [PubMed] [Google Scholar]
  22. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J. J., Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993 Nov;61(5):1828–1834. doi: 10.1111/j.1471-4159.1993.tb09823.x. [DOI] [PubMed] [Google Scholar]
  23. Wilcock G. K., Esiri M. M. Plaques, tangles and dementia. A quantitative study. J Neurol Sci. 1982 Nov;56(2-3):343–356. doi: 10.1016/0022-510x(82)90155-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES